Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) Equity Average (2019 - 2026)

Pliant Therapeutics has reported Equity Average over the past 8 years, most recently at $173.2 million for Q1 2026.

  • Quarterly Equity Average fell 38.29% to $173.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $173.2 million through Mar 2026, down 38.29% year-over-year, with the annual reading at $242.6 million for FY2025, 37.6% down from the prior year.
  • Equity Average was $173.2 million for Q1 2026 at Pliant Therapeutics, down from $190.8 million in the prior quarter.
  • Over five years, Equity Average peaked at $547.5 million in Q2 2023 and troughed at $160.8 million in Q2 2022.
  • The 5-year median for Equity Average is $325.0 million (2024), against an average of $327.3 million.
  • Year-over-year, Equity Average skyrocketed 240.5% in 2023 and then tumbled 43.08% in 2025.
  • A 5-year view of Equity Average shows it stood at $325.2 million in 2022, then skyrocketed by 50.17% to $488.3 million in 2023, then crashed by 33.45% to $325.0 million in 2024, then crashed by 41.3% to $190.8 million in 2025, then dropped by 9.21% to $173.2 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Equity Average are $173.2 million (Q1 2026), $190.8 million (Q4 2025), and $210.2 million (Q3 2025).